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ABSTRACT 36 
Hormones have an important role in regulating fetal development. They act as 37 
environmental signals and integrate tissue growth and differentiation with relation to 38 
nutrient availability. While hormones control the developmental fate of resources available 39 
to the fetus, the actual supply of nutrients and oxygen to the fetus depends on the placenta. 40 
However, much less is known about the role of hormones in regulating placental 41 
development, even though the placenta has a wide range of hormone receptors and 42 
produces hormones itself from early in gestation.  The placenta is, therefore, exposed to 43 
hormones by autocrine, paracrine and endocrine mechanisms throughout its lifespan. It is 44 
known to adapt its phenotype in response to environmental cues and fetal demand signals, 45 
particularly when there is a disparity between the fetal genetic drive for growth and the 46 
nutrient supply. These adaptive responses help to maintain fetal growth during adverse 47 
conditions and are likely to depend, at least in part, on the hormonal milieu. This review 48 
examines the endocrine regulation of placental phenotype with particular emphasis on the 49 
glucocorticoid hormones.  It focuses on the availability of placental hormone receptors and 50 
on the effects of hormones on the morphology, transport capacity and endocrine function 51 
of the placenta.  52 
 53 
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 68 
INTRODUCTION 69 
During development, hormones act as environmental cues in regulating tissue growth and 70 
differentiation in utero.  They signal stress levels, temperature, photoperiod and the 71 
availability of nutrients and oxygen (1). Towards term, hormones also act as maturational 72 
signals in the final processes of tissue differentiation in preparation for delivery (1, 2).  By 73 
regulating intrauterine development in relation to these cues, hormones determine the 74 
phenotype of the offspring and maximise its chances of survival not only during fetal and 75 
neonatal life but also onto reproductive age as an adult (3).  While hormones control the 76 
developmental fate of the resources available to the fetus, the actual supply of nutrients 77 
and oxygen to the fetus depends on the placenta. The placenta is known to adapt its 78 
transport phenotype to help maintain fetal growth in response to external environmental 79 
conditions, such as malnutrition, dietary composition and maternal psychological stresses of 80 
restraint, isolation and inappropriate light exposure (4, 5). It also responds to internal 81 
signals of fetal nutrient demands, particularly when there is a mismatch between the 82 
placental capacity to supply nutrients and the fetal genetic drive for growth (4, 6).  83 
Furthermore, the placenta has endocrine functions itself and can both metabolise and 84 
synthesise hormones (1, 2, 7), which influences fetal development directly and indirectly by 85 
adapting maternal metabolism in favour of resource allocation to the fetus (8).  The 86 
placenta is, therefore, exposed to hormones by autocrine, paracrine and endocrine 87 
mechanisms from early in development. However, compared to the fetus, less is known 88 
about the role of endocrine signals in placental development (2). This review, therefore, 89 
examines the endocrine regulation of placental phenotype. It places particular emphasis on 90 
the glucocorticoids because these hormones act as both environmental and maturational 91 
signals and affect growth and differentiation of many tissues known to be programmed 92 
during intrauterine development (1, 4). It does not consider the role of hormones in human 93 
trophoblast invasion or in the control of placental blood flow more generally.   94 
 95 
PLACENTAL HORMONE RECEPTORS 96 
 97 
Hormones can influence placental phenotype either directly via specific receptors on various 98 
cell types forming the placenta or indirectly by inducing physiological changes in the fetus 99 
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and/or mother, such as alterations in nutrient availability or placental blood flow. The 100 
placenta has receptors for a wide range of circulating hormones, including those it 101 
produces, from early in development in several species (Table 1).  In humans, it also 102 
expresses receptors for opioid, neuro-, growth regulatory and vasoactive peptides that are 103 
produced endogenously to act locally (7). Receptor expression can be ubiquitous or 104 
restricted to specific zones or cell types within the placenta (20, 31, 37, 41, 45, 51, 52, 56, 105 
64). Their abundance may also be sex-linked (9, 14, 26, 69). Multiple isoforms of certain 106 
hormone receptors exist in the placenta and can be expressed selectively or differentially in 107 
the different placental tissues (9, 31, 42, 46, 55, 69).    Some of the variants appear to be 108 
unique to the placenta and not every isoform identified in the placenta is expressed in every 109 
individual (7, 9, 70). In term human placenta, for instance, there are 5 isoforms of the 110 
glucocorticoid receptor (GR) in the endothelium but 12 different variants in the trophoblast, 111 
which are differentially expressed in male and female infants (9).  Consequently, by late 112 
gestation when most fetal endocrine glands are functional (1), the placenta has the 113 
necessary receptors to respond to a range of hormones in both the fetal and maternal 114 
circulations.   115 
 116 
With increasing gestational age, there are changes in placental abundance and spatial 117 
localisation of several hormone receptors including those for insulin, angiotensin, estrogens, 118 
glucocorticoids, adiponectin, leptin and the thyroid hormones (14, 30, 31, 49-51, 58-61, 68).  119 
Some of these developmental changes are isoform specific (31, 49, 58, 61, 68, 70). In the 120 
human placenta, localisation of the insulin receptor (IR) changes with gestational age from 121 
presence primarily in the syncytiotrophoblast facing the maternal circulation in the first 122 
trimester to expression predominantly in the placental endothelial cells facing the fetal 123 
circulation at term (37).  In contrast, the increase in placental GR abundance between mid 124 
and late gestation is more widespread, although the magnitude of the increment may vary 125 
regionally depending on species (11, 15, 49, 69-73). In rats, for instance, the ontogenic 126 
increase in GR is more pronounced in the labyrinthine zone (Lz) responsible for nutrient 127 
transfer than in the junctional zone (Jz), the morphologically distinct region with endocrine 128 
functions (73).  These spatio-temporal changes in placental hormone receptor abundance 129 
indicate that hormones are likely to have a significant role in normal placental development 130 
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and that the relative importance of fetal versus maternal endocrine signals may change as 131 
the metabolic demands of pregnancy increase with fetal growth towards term.  132 
Placental hormone receptor abundance is also responsive to external environmental 133 
conditions (4). There are changes in placental abundance of GR, IR, IGFR1 and Ob-R when 134 
maternal nutritional state is altered by diabetes or dietary manipulation of calorie, macro-135 
and/or micronutrient intake during pregnancy in experimental animals (11, 12, 38, 40, 74-136 
76).  In part, these nutritionally-induced changes in hormone receptor expression may 137 
reflect the concomitant alterations in the endocrine environment as direct experimental 138 
manipulation of maternal hormone concentrations, particularly of the glucocorticoids, alters 139 
placental expression of several hormone receptors including AT2R, Ob-Ra, Ob-Re, FP, EP2, 140 
IGF1R and GR itself (17, 33, 49, 57, 69, 77, 78).  In addition, clinical complications of human 141 
pregnancy that alter placental blood flow or the circulating concentrations of hormones and 142 
metabolites, such as gestational diabetes, intrauterine growth restriction (IUGR) and pre-143 
eclampsia, are associated with changes in placental expression of a range of hormone 144 
receptors including AT1R, GR, GHR, IGF-1R, OB-R, AR and IR  (9, 30, 37, 79-82).  Taken 145 
together, these observations indicate that hormone receptor abundance in the placenta can 146 
vary with gestational age, sex of the offspring and with a range of environmental cues of 147 
fetal and maternal origin. In turn, this will influence the effects that hormones can have on 148 
the morphological, transport and endocrine phenotype of the placenta.  149 
 150 
 151 
HORMONES AND PLACENTAL MORPHOLOGY 152 
 153 
Changes in trophoblast invasion and in the size and morphology of the definitive placenta 154 
have been observed in response to experimental manipulation of both maternal and fetal 155 
hormone concentrations (2, 4, 7). These studies have tended to focus on the glucocorticoids 156 
and insulin-like growth factors because of their known effects on fetal growth (83, 84). 157 
Maternal glucocorticoid administration during the last third of gestation leads to reduced 158 
placental weight in a wide range of species including monkeys, sheep, rabbits, rodents and 159 
human infants (4, 83, 85, 86). The degree of placental growth restriction depends on the 160 
type of glucocorticoid administered, the dose and duration of treatment and the gestational 161 
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age at both treatment and assessment (85, 86).  The growth inhibitory effects are more 162 
pronounced with administration of synthetic than natural glucocorticoids and when 163 
glucocorticoid overexposure occurs in mid to late gestation than close to term (87, 88).  In 164 
rodents, placental growth is also restricted to a greater extent by continuous than 165 
intermittent maternal treatment, irrespective of the exact route of glucocorticoid 166 
administration (86, 88). Furthermore, growth restriction of the rodent placenta occurs in 167 
response to local overexposure to glucocorticoids induced by reducing the activity of 168 
placental 11β-hydroxysteroid dehydrogenase-2 (11βHSD2), the enzyme that normally 169 
converts active glucocorticoids to their inactive metabolites (89, 90).   In contrast, 170 
overexposure of the placenta to glucocorticoids via the fetal circulation appears to have less 171 
severe effects on placental growth, although this may relate, partially, to treatment later in 172 
gestation (91, 92). 173 
 174 
These changes in placenta size and/or weight are accompanied by more specific alterations 175 
in placental morphology. In sheep, glucocorticoids affect the gross morphology of the 176 
placenta whether given maternally or fetally (86). In particular, there is a reduced number of 177 
everted placentomes without a change in total number, which leads to an altered frequency 178 
distribution of the different placentome types with potential consequences for glucose 179 
transport (91).  Glucocorticoid treatment of either the mother or fetus in late gestation also 180 
reduces the numbers of binucleate cells (BNC) in the ovine placentomes (91, 92). These cells 181 
migrate from the fetal trophectoderm across the feto-maternal junction to form a 182 
syncytium with the maternal epithelium. They also produce progesterone and placental 183 
lactogen that influence maternal metabolism and tissue growth. Changes in BNC frequency 184 
and migration induced by glucocorticoid overexposure may, therefore, alter the 185 
morphological remodelling of the placenta and the maternal adaptations to pregnancy with 186 
consequences for resource allocation to the fetus. 187 
 188 
In several species, there are changes in the surface area of the placenta in response to 189 
manipulating placental exposure to the glucocorticoids and IGFs (2, 4, 86). In rodents, 190 
maternal treatment with natural and synthetic glucocorticoids decreases the volume and 191 
surface area of the Lz trophoblast, particularly when treatment coincides with the main 192 
period of placental development (14, 49, 57, 69, 87, 88, 90-92). These changes are coupled 193 
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with a decrease in placental vascularity and Vegf expression, which can persist or reverse 194 
after cessation of treatment depending on the gestational age at time of overexposure (14, 195 
69, 87, 88, 93-96). Similarly, there are reductions in the Lz volume and fetal vascularity of 196 
the mouse placenta locally overexposed to glucocorticoids by deletion of the 11βHsd2 gene 197 
(90). Reduced vascularity of the fetal villi has also been observed in term placenta of 198 
asthmatic women treated clinically with high doses of glucocorticoids during pregnancy 199 
(97).  In mice, high doses of synthetic glucocorticoids have been shown to lead to placental 200 
necrosis and increased expression of several apoptotic genes (94). In contrast to the 201 
glucocorticoids, IGFs increase placental size, Lz volume and vascularity in mice and guinea 202 
pigs (6, 39).  The IGFs also decrease the thickness of the interhemel membrane between the 203 
maternal and fetal circulations (6). However, the extent to which these hormonally induced 204 
changes in placental morphology and vascularity lead to altered placental blood flow still 205 
remains unclear as blood pressure is often elevated in response to glucocorticoid 206 
administration (85, 86).  Nevertheless, changes in placental size and morphology with the 207 
endocrine milieu will alter the placental capacity for transfer of oxygen and nutrients to the 208 
fetus. 209 
 210 
 211 
HORMONES AND PLACENTAL NUTRIENT TRANSPORT 212 
 213 
Using both in vivo and in vitro experimental methods, a wide range of different hormones 214 
have been shown to alter placental uptake and/or transplacental transfer of glucose and 215 
amino acids (Table 2).  In some instances, these changes are associated with altered 216 
placental abundance of the transporters required for active transport of amino acids or 217 
facilitated diffusion of glucose from mother to fetus (Table 2).  Much less is known about 218 
the endocrine regulation of placental lipid transport, although environmental factors such as 219 
maternal obesity and gestational diabetes can influence placental abundance and activity of 220 
the fatty acid transfer proteins involved in fetal uptake of fatty acids (131, 132).  The 221 
hormonally induced changes in trophoblast surface area, thickness and vascularity will also 222 
influence the passive diffusion properties of the placenta and, hence, transport by simple 223 
diffusion of oxygen and waste products like urea and carbon dioxide (2, 5). In addition, both 224 
the glucocorticoids and the IGFs are known to alter placental production of the fetal 225 
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metabolic substrate, lactate, and its distribution between the uterine and umbilical 226 
circulations (91, 117, 118). Furthermore, fetal cortisol infusion has been shown to increase 227 
glucose consumption by the ovine placentomes, thereby limiting the proportion of uterine 228 
glucose uptake that is passed onto the fetus (91). Thus, hormones affect placental delivery 229 
of nutrients to the fetus not only by altering the morphological and functional 230 
characteristics of the actual transport processes but also by actions on the production and 231 
consumption of nutrients by the placenta per se. 232 
 233 
Not all hormonal actions on placental nutrient delivery are direct. Some are mediated 234 
indirectly by physiological actions in the mother and fetus or by effects on energy 235 
availability for active transport or on the sodium concentration gradient used to drive 236 
secondary active, sodium-coupled amino acid transport (133).  For example, the inhibitory 237 
effect of angiotensin II on sodium dependent MeAIB transport in human placental villous 238 
fragments appears to be mediated by AT-1R induced down-regulation of Na+-K+ ATPase 239 
activity that maintains the transcellular sodium concentration gradient (130). With simple or 240 
facilitated diffusion, the hormonal effects on transport may be the result of alterations in 241 
placental blood flow or the transplacental concentration gradients driving net transfer. For 242 
instance, insulin administration to pregnant ewes lowers maternal glucose levels and 243 
reduces facilitated diffusion of maternal glucose to the fetus in proportion to the decrease 244 
in the transplacental concentration gradient (111). Thus, insulin appears to have little direct 245 
effect on the placental capacity for glucose transport per se in sheep in late gestation with 246 
no changes in placental glucose transporter (GLUT) abundance or glucose partitioning in the 247 
short term (111, 112, 132).  Similarly, insulin has no effect on glucose uptake by villous 248 
fragments of term human placenta in vitro (122).   When insulin infusion is more prolonged 249 
in pregnant ewes in vivo, there are changes in placental GLUT expression in line with the 250 
reduced glucose transport, although whether these changes are the consequence of the 251 
sustained hyperinsulinaemia or of the concomitant hypoglycaemia still remains unclear 252 
(111, 112, 134).  However, in rats, short term insulin infusion in euglycaemic conditions has 253 
been shown to increase placental glucose uptake at day 19 of pregnancy but not closer to 254 
term (114).  In in vitro studies, insulin has been shown to increase amino acid uptake by 255 
villous fragments of term human placenta after periods of between 2-24h in culture (110, 256 
122, 130). These actions of insulin and IR localisation suggest that insulin may be involved in 257 
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the growth and remodelling of the placenta from early in gestation and, particularly, the 258 
placental vasculature nearer to term (37). However, like the brain, uptake and utilisation of 259 
glucose by the placenta appears to be insulin insensitive, despite the presence of insulin 260 
receptors (Table 1), which probably relates to the lack of insulin-sensitive glucose 261 
transporters, GLUT4, in the placenta (135).  262 
 263 
In part, the effects of hormones on nutrient transfer depend on their route of 264 
administration and on whether measurements are made during or after ending treatment. 265 
Short term infusion of IGF-I increased placental lactate production when given maternally 266 
but not fetally while, conversely, umbilical uptake of glucose is increased with fetal but not 267 
maternal administration in the sheep (117, 118). In both sheep and mice, glucocorticoid 268 
overexposure during late gestation reduces placental transport of glucose and amino acids 269 
during the period of overexposure, irrespective of its duration, method of induction, or the 270 
type of glucocorticoid involved (Figure 1). In contrast, after glucocorticoid treatment, 271 
transport of glucose and amino acids by the growth restricted mouse placenta tends to 272 
increase compared to age matched controls, although the precise response appears to 273 
depend on the interval between ending treatment and measuring transport (Figure 1).  In 274 
part, the up-regulated nutrient transport seen after treatment may reflect an increased 275 
demand for nutrients from the growth restricted fetus once the glucocorticoid has cleared 276 
from the tissues.  Indeed, increased placental nutrient transport, particularly of the amino 277 
acids, is also seen when there is a disparity between the placental capacity to supply 278 
nutrients and the fetal nutrient demands for growth, irrespective of whether this mismatch 279 
is induced nutritionally or genetically (4, 6).   280 
 281 
When all the mouse transport data at day 19 of pregnancy are combined, irrespective of the 282 
period of corticosterone treatment, there is a significant inverse correlation between 283 
maternal corticosterone concentrations and placental MeAIB transport (87).  This is 284 
consistent with the concept that there is a dynamic balance in resource allocation between 285 
the mother and fetus that is responsive to environmental conditions (4, 8).  By reducing 286 
placental size and nutrient transport, increased maternal glucocorticoids levels spare 287 
nutrients for maternal use during stressful periods and, by limiting fetal growth, further 288 
reduce the nutritional demands on the mother if the stress is prolonged. Conversely, when 289 
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maternal stress and glucocorticoid levels are low, more maternal nutrients can be diverted 290 
to the gravid uterus, particularly when there is an increased demand signal from fetuses 291 
growth restricted below their genetic potential by earlier periods of adverse environmental 292 
conditions.  293 
 294 
HORMONES AND PLACENTAL ENDOCRINE FUNCTION 295 
 296 
The placenta produces a wide range of hormones including sex steroids, eicosanoids, 297 
glycoprotein and peptide hormones, some of which are unique variants of pituitary 298 
hormones (1, 7). Secretion of several of these is sensitive to the endocrine milieu and, 299 
particularly, to the glucocorticoids (Table 3).  Increasing placental exposure to 300 
glucocorticoids in vivo in late gestation has been shown to increase placental production of 301 
PGE2 and estrogen, and reduce secretion of placental lactogen, leptin, IGF-I and the family 302 
of prolactin hormones depending on the specific species (Table 3). In rodents, these changes 303 
are often Jz specific (93, 147). Similarly, glucocorticoids have been shown to alter secretion 304 
of leptin, placental GH, hCG and PGE2 by human villous fragments and trophoblast cell lines 305 
in vitro (Table 3).   In most species studied to date, glucocorticoid-induced changes in 306 
placental hormone production form part of the normal sequence of prepartum 307 
maturational events that ensure fetal maturation is co-ordinated with the onset of labour 308 
and lactation (1, 151). However, changes in placental hormone production induced by 309 
glucocorticoids earlier in gestation as a result of stressful conditions can have adverse 310 
consequences for fetal development, maternal recognition of and metabolic adaptation to 311 
pregnancy as well as for lactation. Indeed, in mares, preterm changes in placental 312 
progestagen production induced by stress or more direct glucocorticoid administration are 313 
associated with prepartum running of milk, poor colostrum production at birth and failure 314 
of foals to thrive postnatally if they are not given supplementary immunoglobulins (152).  315 
 316 
The placental endocrine phenotype depends not only on the production of hormones but 317 
also on their metabolism. In several species including rodents, sheep and humans, the 318 
placenta inactivates glucocorticoids and prostaglandins, thereby reducing their circulating 319 
and placental bioavailability.  In turn, the inactivating enzymes are responsive to hormones 320 
(1, 2, 83). Both progesterone and cortisol have been shown to regulate placental activity of 321 
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11βHSD2 and prostaglandin dehydrogenase (PGDH), the enzymes responsible for 322 
inactivating glucocorticoids and prostaglandins, respectively (83, 85).  However, the specific 323 
response of these placental enzymes to hormonal signals depends on species, gestational 324 
age, duration of treatment and maternal nutritional state (2, 83, 149).  325 
 326 
CONCLUSIONS 327 
Hormones in the fetal and maternal circulations have an important role in determining 328 
placental phenotype (Figure 2). They signal fetal wellbeing and maternal environmental 329 
conditions to the placenta, respectively. In turn, placental hormones signal resource 330 
availability to the fetus and fetal nutrient demands to the mother based on the genetic drive 331 
and current mass of the fetus (Figure 2).  The placenta integrates all these hormonal signals 332 
and adapts its phenotype to optimise resource allocation between the mother and growing 333 
fetus with respect to both fetal and maternal fitness. The hormonally-induced adaptations 334 
can be either short lived to allow a rapid response to environmental change or persist to 335 
transmit memories of earlier events to the fetus later in development. Endocrine regulation 336 
of placental phenotype, therefore, provides a unifying mechanism for determining the 337 
phenotype of the offspring that develops from the genotype inherited at conception. 338 
However, little is yet known about the specific cellular and molecular pathways in the 339 
placenta that sense the hormonal signals and then mediate the adaptive responses. Nor is it 340 
clear whether hormones alter the placental epigenome, although epigenetic modifications 341 
in the placenta occur during normal development and growth restriction as well as in 342 
several other clinical complications of human pregnancy (6, 153, 154).  343 
 344 
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 356 
FIGURE LEGEND 357 
 358 
Figure 1:  Effects of glucocorticoids during and after treatment on placental transport of 359 
glucose and amino acids in sheep and mice during late gestation. In sheep, placental 360 
glucocorticoid overexposure was increased by fetal intravenous treatment with either for 361 
cortisol for 5 days (Cort, hatched columns) or dexamethasone for 24h (Dex, grey columns) 362 
and measurements of transport made during the final hours of treatment. In mice, placental 363 
overexposure was induced either to the synthetic glucocorticoid, dexamethasone (Dex, grey 364 
columns) by maternal administration for 5 days or to the natural glucocorticoid, 365 
corticosterone (Cort, hatched columns), by deletion of the 11βhsd2 gene or maternal 366 
corticosterone administration for 5 days. In the mice, transport measurements were made 367 
either during overexposure (during treatment) alone and/or after cessation of treatment 368 
(after treatment with the timing indicated as + days from ending treatment). All values are 369 
expressed as % of that in the control animals (open columns).  370 
* significantly different from control by the statistical analyses used in the relevant study. 371 
Data from references 87, 88, 90, 91, 101-103, 106 and 107. 372 
 373 
 374 
Figure 2:  A schematic diagram showing the role of hormones in regulating placental 375 
phenotype with respect to balancing maternal resource availability with fetal resource 376 
demands for optimal intrauterine growth.  377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
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Table 1:  Presence of hormone receptors in the placenta with respect to gestational age in different species.  
(d = days, w = weeks. Term : human 40 weeks, horse 335 days, cow 280 days, baboon 168 days, sheep 145 days, pig 115 days, guinea pig 70 days, cat 65 days, 
rabbit 30 days, rat 22 days, spiny mouse 39 days, mouse 20 days)  
 
 Hormone 
group 
Specific Receptor 
(Abbreviation) 
Isoforms Species  Gestational age 
(days,d/weeks, w) 
Reference 
Steroids Glucocorticoids (GR) GRα, GRβ Human 
Sheep 
Pig 
Rat 
Spiny Mouse 
Mouse 
Term 
51-140d 
94d 
16-22d 
23-37d 
9.5d - term 
9 
10, 11 
12 
13 
14  
15  
 Mineralocorticoids (MR) MR Human 
Pig 
Sheep 
5-40 w 
94d 
138d 
16 
12  
17 
 Estrogens  (ER) ERα, ERβ Human 
Horse 
Sheep 
Rabbit 
Term 
110-309d 
13-30d  
10-14d 
18, 19 
20 
21  
22  
 Progesterone (PR) PR-A, PR-B Human 
Horse 
Sheep 
Rabbit  
Rat 
Term 
110-199d 
30d & 84-112d 
10-16d 
12d 
19, 23  
20 
21, 24 
22 
25 
 Androgens (AR) AR-A, AR-B Human 
Cow 
Rat 
16w - term 
50d – term 
21d 
26 
27 
28 
Iodothyronines Thyroid hormones (TR) TRα, TRβ Human 
Rat 
13w - term 
16-21d 
29, 30 
31  
Eicosanoids Prostaglandins (PG) PGE2 
                                      
                                    PGF2α 
EP1,2,3 & 4 
 
FP 
Human 
Sheep 
Human 
Sheep 
38-41w 
Term 
38-41w 
Term 
32 
33  
32 
33 
27 
 
27 
 
Glycoproteins Chorionic gonadotrophin  LH receptor 
TGFβ receptor2 
Human 
Horse 
Term 
27-34d 
34  
35  
Proteins Insulin (IR) IR-A, IR-B Human 
Monkey 
Rat 
Mouse 
1st trimester & term 
Near term 
Term 
16-19d 
36, 37 
36 
36 
38  
 Insulin-like  
growth factors (IGFR) 
IGFR1,  IGFR2 Human 
Sheep 
Guinea pig 
Rat 
Mouse 
1st trimester & term 
138d 
35d 
21d 
16-19d 
37 
11, 17  
39  
40 
38 
 Prolactin (PRLR) PRL-R  Human 
Baboon 
Rat 
Term 
39d & Term 
15-17d & 19d 
41, 42  
43 
41, 44  
 Leptin (OBR) Ob-Ra, Ob-Rb Human 
Baboon 
Sheep 
Pig 
Cat 
Rat 
Mouse 
Term 
60-164d 
128d 
30d & 100d 
Term 
16-22d 
11.5-18.5d 
45  
46  
47  
47  
48  
49  
50  
 Adiponectin Adipo-R2  Human 
Rat  
1st trimester & term 
12-21d 
51  
51 
 Growth hormone (GHR) GHR Human 
Sheep 
8w & Term 
20-120d 
7 
52, 53  
 Corticotrophin Releasing 
Hormone (CRH) 
CRH-R1, CRH-R2 Human  Term  54, 55 
 Kisspeptin Kiss1R Human 
Rat 
Term 
16d & 22d 
56 
57 
Peptides Gonadotrophin releasing 
hormone (GnRHR) 
GnRHR-I & -II Human 6-20w 58 
 Angiotensin (ATR) AT1R, AT2R Human 
Sheep 
10w-term 
27-140d 
59  
60, 61  
28 
 
28 
 
Pig 
Rabbit 
Mouse 
30d-term 
14-28d 
16.5d & 18.5d 
62 
63  
64 
 ANP  Human Term 65 
 Adrenomedullin  Human 
Cow 
Rat 
Term 
200d 
12d & 17d 
66 
67 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
29 
 
 
Table 2: Effect of hormone administration on the transport phenotype of the placenta in different species with respect to gestational age at treatment and assessment. 
                    
Hormone 
 
 
Species 
 
Type and route of treatment 
Gestational age (days) 
At treatment           At study 
 
Placental transport phenotype 
 
 
Reference 
Glucocorticoids  Human 
-in vitro 
Cortisol  In culture  
 
Dex In culture 
Cell line 
Term 
Term 
Cell line +24h 
Term 
Term 
↑ MeAIB uptake ↑SNAT2 
↑ Na+/H+ exchanger activity 
↑ MeAIB uptake  
98 
99 
100 
 Sheep  
-in vivo 
Fetal cortisol iv infusion 
 
 
Fetal dex iv infusion 
120-122 
125-130d 
 
Near term 
120-122 +6h 
130d 
 
Near term 
+24h 
↓ Amino-nitrogen delivery 
↓ Glucose delivery 
↑ Glucose consumption  
↓ Alanine delivery 
↓ Glutamate uptake 
↑ Placental lactate delivery 
↓ Glucose delivery 
101  
91 
91 
102 
102 
102 
103 
 Rat 
-in vivo 
Maternal dex sc infusion 
Maternal dex sc injection 
15-21d 
15-19d 
21d 
20d 
↑ GLUT 1 & 3 
↑ Folate transport ↓ Choline transport 
104 
105 
 Spiny mouse 
-in vivo 
Maternal dex sc infusion 20-22.5d 23d  
37d 
↓ SLC2A1 
↓ SLC2A1 – males only 
14 
14 
 Mouse 
-in vivo 
Maternal corticosterone po 
In drinking water 
 
 
Maternal dex po 
Maternal dex  sc injection 
11βHsd2 null 
11-16d 
11-16d 
 
14-19d 
11-16d 
13.5 & 14.5d 
Conception 
Conception 
16d 
19d 
 
19d 
19d 
18.5d 
15d 
18d 
↑Slc38a1&2 ↓Slc2a1 & 3 
↑ MeAIB transport  ↑Slc38a1 
↑ Glucose transport 
↓ MeAIB transport 
↑ MeAIB transport 
↓ MeAIB transport 
↑ MeAIB transport ↑Slc38a2 
↓ Glucose transport ↓Slc2a3 
87, 106 
87 
106 
87 
88 
107 
90 
90 
Aldosterone  Human 
-in vitro 
In culture Term Term ↑ Na+/H+ exchanger activity 
 
99 
 
Testosterone Rat 
-in vivo 
Maternal sc injection 
 
15-19d 21d ↓ MeAIB uptake & transport  ↓SNAT2 108 
Estrogen Rat 
-in vivo 
Maternal po daily 4-8d 13d ↓ GLUT1 109 
30 
 
30 
 
Insulin  Human  
-in vitro 
In culture Term Term +24h ↑ MeAIB uptake 110 
 
 Sheep 
-in vivo 
Maternal iv infusion 
 
Fetal iv infusion 
105d 
 
135d 
130-141d 
 
135d +4h 
↓ Glucose utilisation & delivery  
↓ GLUT1  
↑ Glucose delivery 
111 
112 
113 
 Rat 
-in vivo 
Maternal iv infusion 
 
19d 19d +4h ↑ Glucose uptake & utilisation 114 
Insulin-like growth factors 
(IGFs) 
Human 
-in vitro 
In culture 1st Trimester 
Term 
1st Trimester 
Term 
↑ Glucose and amino acid uptake  
↑ MeAIB uptake 
115 
116 
 Sheep 
-in vivo 
Maternal  iv infusion 
Fetal iv infusion 
132d 
130d 
 
120-130d 
132d +4h 
130d +4h 
 
130d 
↑ Placental lactate production & delivery 
↓ Placental lactate production & delivery 
↑ Glucose delivery 
↓ Glucose and MeAIB clearance 
117 
118 
118 
119 
 Guinea pig 
-in vivo 
Maternal sc infusion 
 
20-35d 
20-38d 
35d 
60d 
↑MeAIB uptake & transport 
↑ Glucose uptake & transport 
120 
121 
Growth hormone Human 
-in vitro 
In culture 1st Trimester 
Term 
1st Trimester 
Term 
↓ MeAIB uptake  
↑ Glucose uptake 
122 
122 
 Pig 
-in  vivo 
Maternal iv injection daily 25-50d 50d ↑ GLUT1, ↑ SNAT2 123 
 Sheep 
-in vivo 
Maternal sc daily injections 
 
125-135d 135d ↑ Placental glucose clearance 
↑ Placental capacity for simple diffusion 
124 
124 
Leptin Human 
-in vitro 
In culture Term 
 
Term +1h 
 
↑ MeAIB uptake 
 
125 
 
Parathyroid related 
protein (PTHrP) 
Mouse 
-in vivo 
PTHrP null Conception 18d ↑Materno-fetal calcium flux 126 
Adiponectin Human 
-in vitro 
In culture Term Term +24h ↑ MeAIB uptake 
 
127 
 Mouse 
-in vivo 
Maternal sc infusion 
 
14.5-18.5d 18.5d ↓ System A and L amino acid transport 
↓ SNAT1, 2 & 4, ↓ LAT1 &2 
128 
Corticotrophin releasing 
Hormone (CRH) 
Human 
-in vitro 
In culture Term  Term +24h ↓ MeAIB uptake  
 
129 
Angiotensin II Human 
-in vitro 
In culture Term Term +4h ↓ MeAIB  uptake  
↓ Na+-K+ATPase activity 
130 
130 
31 
 
31 
 
 
po  = per os,  iv =  intravenous,  sc =  subcutaneous, Slc38a 1&2 and SNAT 2 & 4 = Sodium coupled neutral amino acid transporter genes and proteins,  
Lat 1 & 2 = L-type amino acids transporters, GLUT 1 & 3 = glucose transporters, Dex = Dexamethasone 
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Table 3: Effect of hormone administration on the endocrine phenotype of the placenta in different species with respect to gestational age at treatment and assessment. 
                    
Hormone 
 
 
Species 
 
Type and route of treatment 
Gestational age (hours/days) 
At treatment           At study 
 
Placental endocrine phenotype 
 
 
Reference 
Glucocorticoids  Human 
-in vitro 
 
 
 
-in vivo 
Dex in culture 
 
 
Cortisol in culture 
 
Dex im 
Beta im x3 daily 
Dex im x3 daily  
Cell line 
Term 
Term 
Cell line  
Term 
3rd trimester 
3rd trimester 
3rd trimester 
Cell line +72h 
Term +72h 
Term +96h 
Cell line + 72h 
Term +144h 
3rd trimester  +5h 
3rd trimester  +48h 
3rd trimester  +7d 
↑ hCG 
↑ Leptin 
↓ PGE2 
↓ Placental GH 
↑ hCG 
↓ Estradiol and estrone  
↑ CRH 
↓ Placental lactogen 
136  
137 
138 
139  
140  
141  
142  
143  
 Cow 
-in vitro 
Dex in culture Term Term + 18h ↓ PGF2α 144 
 Sheep  
-in vivo 
Maternal beta im 3x 
Fetal dex iv infusion 
Fetal beta im injection 
Fetal cortisol iv infusion 
103-118d 
Term 
131d 
125-128d 
109-121d 
Term 
134d 
128-131d 
↓ Placental lactogen  
↓ Progesterone, ↑ Estrogens 
↑ PGE2, ↑ PGF2α 
↑PGE2 ↑Estrogens 
92 
145 
146 
147 
 Rat 
-in vivo 
Maternal dex sc infusion 
 
13-20d 
15-21d 
20d 
21d 
↓ IGF-II, ↓ Prolactin gene family  
↓ Leptin 
93 
148 
 Spiny mouse 
-in vivo 
Maternal dex sc infusion 20-22.5d 23d & 37d ↓ IGF-I 14 
 Mouse 
-in vivo 
Maternal dex ip injection 
daily 
7.5-9.5d 18.5d ↓ PLII, ↓ Prp 149 
Testosterone Rat 
-in vivo 
Maternal sc injection 
 
16-19d 21d ↑Estrogen 28 
Progesterone  Human  
-in vitro 
In culture Term 
 
Term  +144h 
 
↓hCG 
 
140 
 
Insulin  Human  
-in vitro 
In culture Term 
Cell line 
Term +72h 
Cell line + 72h 
↑ Leptin 
↓ Placental GH 
137 
143 
Insulin-like growth 
factors (IGF) 
Human 
-in vitro 
In culture – IGF-I Cell line Cell line +24h ↑ hCG, ↑ Progesterone 150 
33 
 
33 
 
Leptin Human 
-in vitro 
In culture Cell line Cell line +72h ↓ Placental GH 139 
 
im = intramuscular,  iv =  intravenous,  sc =  subcutaneous, ip = intraperitoneal,  hCG = human chorionic gonadotrophin, GH = growth hormone, PGE2 = 
Prostaglandin E2, PGF2α = Prostaglandin F2α, CRH = Corticotrophin releasing hormone, IGF = Insulin-like growth factor – I and –II, PLII = Placental lactogen II 
gene, Prp = Prolactin related protein gene, Dex = dexamethasone, Beta = Betamethasone. 
 
 
